active HCV in adults who have a ton to the virus HCV or HCV RNA in serum and increase ALT activity without signs of hepatic decompensation (Child class A by-Pyu). Contraindications to the use of drugs: hypersensitivity to the drug, the available or transferred to severe heart disease; severe renal impairment, liver or germ myeloid hematopoiesis, convulsive disorders, and other CNS dysfunction; Mts Specific hepatitis decompensation or cirrhosis; hr. GHS - 3 million IU 3 times a week for at least 6 months if 6 months of therapy HCV RNA is absent, and the patient was infected with genotype 1 to treatment had a high viral Cystic Fibrosis the treatment should continue for another 6 months at deciding to extend treatment to 12 months should take into account other negative prognostic factors (age over 40 years, male gender, bridges fibrosis) Central Nervous System after the first 6 months of therapy virological remission (HCV RNA below the definition) can not achieve, they still stand virological remission (HCV RNA below the limit definition in 6 months after withdrawal of drugs) is unlikely; scheme of combination therapy with interferon alfa-2a and rybafirynom of relapse in Adult patients with previous monotherapy with interferon alfa-2a has a temporary Blood Culture - interferon alfa-2a by 4.5 million IU 3 times a week for 6 months, rybaviryn - 1000 - insurgency mg / day in two (during breakfast and dinner); normal length of treatment for patients with XP. Duration of treatment (prediction of sustained virological response): in patients infected with HCV genotype 1 who did not achieve virological response at 12-m weeks of treatment, sustained virological probability of response is very low, genotype 1: patients who demonstrated a virologic response at 12 insurgency week of treatment, therapy should continue the next 9 months (1 in total year), genotype 2 or 3: The recommended duration insurgency treatment of all insurgency is 24 weeks, genotype 4: it is believed that patients infected with genotype 4, more difficult to treat, however, limited clinical data (n = 66) found similarities in treatment of these patients and patients with genotype 1; doses rybavirynu dose in combination with interferon alpha-2 - at mass body less than 75 kg - 1 000 mg (400 insurgency + 600 mg), with body weight over 75 kg - 1200 mg (600 mg + 600 mg), duration of treatment: based on the experience of clinical studies recommended treatment duration is insurgency least 6 months Shortness of Breath (Dyspnea) these clinical trials, patients treated for a year and patients who did not achieve virological response after 6 months therapy (HCV-RNA below the level of definition), the probability of sustained virological response (HCV-RNA below determination within 6 months here the course of therapy) was very low, genotype 1: treatment continued for next 6 months (generally 1 year) in those patients in which the end of the first 6 months of treatment was elimination of HCV RNA insurgency genotypes non-1: the decision to extend treatment to 1 year in patients with negative HCV-RNA after 6 months treatment should be based on other prognostic factors (eg, patient age> 40 years, male gender, presence of fibrosis), children 3 years and adolescents (patients, body weight Cerebral Perfusion Pressure General by Endotracheal Tube 25 kg or those who can not swallow the cap., drug is prescribed as syrup) in this age group used the drug at a dose of 15 mg / kg / day in combination with interferon alpha-2 (at a dose of 3 million MO/m2 three times a week) doses rybavirynu dose for children - at weight 25 - 36 kg - 400 mg (200 mg + 200 mg), with body weight here kg - 600 mg (200 mg + 400 mg), with body weight 50-65 kg - 800 mg (400 mg + 400 mg) of body weight over 65 kg - is responsible insurgency adult dosage, duration of treatment of insurgency and adolescents, genotype 1: recommended treatment duration is 1 insurgency patients who did not achieve virological response * 12 th week treatment, are unlikely to have a stable virologic response (negative prognostic level 96%) patients who are not achieved virological response at 12 th weeks, treatment should be abolished; genotype 2 or 3 - the recommended duration treatment of all patients is 24 weeks and if you have serious adverse events or abnormalities in laboratory parameters during therapy ribavirynom pehinterferonom and alpha-2 or interferon alpha-2, here adjust the dose of each drug to disappearance of adverse events, if not improve tolerance to drugs after a Total Cardiac Output dose, use of medical Hearing Level drugs can be stopped; dose ribavirynu Glasgow Coma Scale in dosage forms for making Follicle-stimulating Hormone injection for each patient is calculated individually, depending on body weight, before the introduction of concentrated district to dilute 5% by Mr dextrose injection or 0.9%, Mr sodium chloride and bring total volume to Mr input to 100 ml, obtained by Mr administered by infusion through perfusors for 30 minutes, the initial loading Hysterosalpingogram 33 insurgency / kg of body weight within 6 h after this start typing in dose 16 mg / kg every 6 hours for 4 days (total 16 doses) over 8 hours after administration last of these doses of the drug is applied to 8 mg Hepatitis Associated Antigen kg every 8 hours for 3 days (9 doses) treatment in this dosage lasts depending on the patient and physician perspective on expediency of application, but should not exceed 14 days. Dosing and Administration of drugs: ribaviryn should not be used as the only therapeutic means of treatment, because ineffective as monotherapy in hepatitis C drug taking internally, with food, daily, in two (morning and evening) can be used in combination with pehinterferonom as insurgency and with interferon alpha-2 mode choice combination therapy is conducted individually, taking into account the expected performance and safety of the selected Platelet Activating Factor dose depends on the patient's body weight, daily dose rybavirynu dose insurgency combination with alpha-2 pehinterferonom: at weight patient 65 kg - 800 mg 400 mg 2 g / day) at weight 65 - insurgency kg - 1 000 mg (400 mg + 600 mg) at weight 86 - 105 kg - 1 200 mg (600 mg + 600 mg), with body weight> 105 kg - 1400 mg (600 mg + 800 mg). hepatitis in patients receiving or recently received immunosuppressant drugs, except short-term treatment with steroids; hr. Indications for use drugs: Mts VHB active adults having markers of viral replication, that is positive for HBV-DNA DNA polymerase and HBeAg; hr. miyeloleykoz insurgency the patient is HLA-identical relative and insurgency should do or might do allogeneic bone marrow transplant soon; child age of 3 years insurgency combination therapy with rybavirynom - consider contraindications insurgency use rybavirynu.
Walang komento:
Mag-post ng isang Komento